MiMedx Group, Inc. (MDXG) Stock

MiMedx Group, Inc. specializes in the development and distribution of placental tissue allografts across various healthcare sectors. Utilizing its patented and proprietary PURION process, the company processes human placental tissues to produce allografts that retain the tissues' natural biological properties and regulatory proteins. This innovative processing method combines aseptic techniques with terminal sterilization to ensure product safety and efficacy.

The company's product portfolio includes EpiFix, a semi-permeable protective barrier membrane used in the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Another key product, AmnioFix, consists of dehydrated human amnion/chorion membrane and is employed in surgical recovery applications. Additionally, MiMedx offers EpiCord and AmnioCord, which are dehydrated human umbilical cord allografts that support healing processes in advanced wound care and surgical recovery.

AMNIOBURN, another product from MiMedx, serves as a semi-permeable protective barrier allograft utilized in treating partial-thickness and full-thickness burns. The company's lead product, mdHACM, is a micronized form of AMNIOFIX available in powder form. These products find applications primarily in wound care, burn treatment, surgical procedures, and non-operative sports medicine within the healthcare industry.

Headquartered in Marietta, Georgia, MiMedx Group, Inc. markets its products through a direct sales force, independent sales agents, and distributors primarily across the United States. Beyond healthcare applications, the company also supplies allografts for dental applications on an original equipment manufacturer basis. With a commitment to innovation and quality, MiMedx continues to advance the field of regenerative medicine, enhancing patient care and recovery outcomes worldwide.